GlassScriptPhysician profile
Frank Lyons Greenway, III
NPI 1134456999
$42,493.24
in general payments reported to CMS, 2019-2025
10 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $14K · 2021: $1,850 · 2022: $17.28 · 2023: $34.49 · 2024: $1,761 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,190 · Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,085.98 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,190.00 |
| Food and Beverage | $799.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $24,756.90 | 2024-2025 | |
| Dr.Reddy'S Laboratories,INC. | $10,000.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $4,250.00 | 2020 | |
| Pfizer INC. | $2,150.00 | 2019-2021 | |
| Dexcom, INC. | $1,190.00 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $94.57 | 2025 | Wegovy |
| Lilly USA, LLC | $51.77 | 2022-2023 | Mounjaro |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Greenway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.